LCAM
AZN icon

London & Capital Asset Management’s AstraZeneca AZN Stock Holding History

London & Capital Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,574
Closed -$289K – 226
2025
Q4 		$289K Buy
+1,574
New +$276K ﹤0.01% 211

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

London & Capital Asset Management's AZN Position: Q1 2026 in Review

London & Capital Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,574 shares — an estimated $289K sold.

London & Capital Asset Management first reported a position in AZN in Q4 2025 and held it in 1 quarter. The position peaked at $289K in Q4 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • London & Capital Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • London & Capital Asset Management sold 1,574 AstraZeneca shares in Q1 2026, an estimated $289K.
  • London & Capital Asset Management first reported a position in AstraZeneca in Q4 2025 and held it in 1 quarter.
  • London & Capital Asset Management's AstraZeneca position peaked at $289K in Q4 2025.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on London & Capital Asset Management's 13F filing for Q1 2026, filed 15 May 2026.